Date: 2016-01-27
Type of information: Collaboration agreement
Compound: human microbiome translational research programme
Company: Ferring Pharmaceuticals (Switzerland) Karolinska Institutet (Sweden)
Therapeutic area: Gastrointestinal diseases - Digestive diseases
Type agreement: collaboration R&D
Action mechanism:
Disease:
Details: * On January 27, 2016, Ferring Pharmaceuticals and Karolinska Institutet announce that a collaboration agreement has been signed for the establishment of a research center exploiting the human microbiome. The programme will be fully funded by Ferring Pharmaceuticals and governed by a joint steering committee. The proposed project focuses on therapeutic areas where Ferring has extensive expertise. Karolinska Institutet has a deep understanding of the human microbiome. Parts of the research will be carried out at the Science for Life Laboratory (SciLifeLab) that provides access to a broad technical platform for studying complex microbiological communities in well-defined human material. The collaboration between the two partners form a solid foundation for the ambition of a better understanding of the contribution of the human microbiome to physiology and patlhophysiology and opens opportunities for development of novel therapies. The research will be led by Professor Lars Engstrand, Karolinska Institutet, who will serve as director. The center will further establish an internationally competitive infrastructure with focus on translational research in the microbiome field set up to develop a comprehensive mapping of the human microbiome in health and disease.
Financial terms:
Latest news:
